nodes	percent_of_prediction	percent_of_DWPC	metapath
Tazarotene—Retinoids—Acitretin—psoriasis	0.586	1	CiPCiCtD
Tazarotene—RARG—Acitretin—psoriasis	0.087	0.264	CbGbCtD
Tazarotene—RXRB—Acitretin—psoriasis	0.0769	0.233	CbGbCtD
Tazarotene—RARB—Acitretin—psoriasis	0.0769	0.233	CbGbCtD
Tazarotene—RARA—Acitretin—psoriasis	0.0769	0.233	CbGbCtD
Tazarotene—CYP2C8—Cholecalciferol—psoriasis	0.00328	0.00996	CbGbCtD
Tazarotene—CYP2C8—Mycophenolate mofetil—psoriasis	0.00285	0.00863	CbGbCtD
Tazarotene—CYP2C8—Hydrocortisone—psoriasis	0.00228	0.00693	CbGbCtD
Tazarotene—CYP2C8—Cyclosporine—psoriasis	0.00216	0.00654	CbGbCtD
Tazarotene—CYP2C8—Dexamethasone—psoriasis	0.00142	0.00431	CbGbCtD
Tazarotene—RXRB—Vitamin D Metabolism—VDR—psoriasis	0.000951	0.0516	CbGpPWpGaD
Tazarotene—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000723	0.0392	CbGpPWpGaD
Tazarotene—Stinging—Clobetasol propionate—psoriasis	0.000583	0.00879	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methoxsalen—psoriasis	0.000565	0.00852	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000515	0.0279	CbGpPWpGaD
Tazarotene—Dry skin—Calcipotriol—psoriasis	0.000503	0.00758	CcSEcCtD
Tazarotene—Dermatitis contact—Clobetasol propionate—psoriasis	0.000467	0.00704	CcSEcCtD
Tazarotene—Blister—Methoxsalen—psoriasis	0.000466	0.00703	CcSEcCtD
Tazarotene—Hypertriglyceridaemia—Acitretin—psoriasis	0.000464	0.007	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000462	0.0251	CbGpPWpGaD
Tazarotene—RARG—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.000459	0.0249	CbGpPWpGaD
Tazarotene—Application site irritation—Hydrocortisone—psoriasis	0.000454	0.00684	CcSEcCtD
Tazarotene—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000448	0.0243	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Fluocinolone Acetonide—psoriasis	0.000447	0.00674	CcSEcCtD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000443	0.024	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000443	0.024	CbGpPWpGaD
Tazarotene—Localized exfoliation—Triamcinolone—psoriasis	0.000441	0.00664	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—REL—psoriasis	0.000426	0.0231	CbGpPWpGaD
Tazarotene—Dermatitis contact—Fluocinonide—psoriasis	0.000421	0.00635	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—CARM1—psoriasis	0.00042	0.0228	CbGpPWpGaD
Tazarotene—Blister—Calcitriol—psoriasis	0.000416	0.00627	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000416	0.0225	CbGpPWpGaD
Tazarotene—Cheilitis—Mycophenolic acid—psoriasis	0.000412	0.00622	CcSEcCtD
Tazarotene—RARB—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.000412	0.0223	CbGpPWpGaD
Tazarotene—Blood triglycerides increased—Acitretin—psoriasis	0.000407	0.00613	CcSEcCtD
Tazarotene—Skin exfoliation—Fluocinonide—psoriasis	0.000407	0.00613	CcSEcCtD
Tazarotene—RXRB—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.000395	0.0214	CbGpPWpGaD
Tazarotene—RARA—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.000395	0.0214	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors—VDR—psoriasis	0.00038	0.0206	CbGpPWpGaD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000373	0.0202	CbGpPWpGaD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000359	0.0195	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000357	0.0194	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Hydroxyurea—psoriasis	0.000352	0.0053	CcSEcCtD
Tazarotene—Swelling—Fluocinonide—psoriasis	0.00035	0.00528	CcSEcCtD
Tazarotene—Inflammation—Methoxsalen—psoriasis	0.000347	0.00523	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—VDR—psoriasis	0.000341	0.0185	CbGpPWpGaD
Tazarotene—Erythema—Calcipotriol—psoriasis	0.00033	0.00498	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptors—VDR—psoriasis	0.000327	0.0177	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptors—VDR—psoriasis	0.000327	0.0177	CbGpPWpGaD
Tazarotene—Cheilitis—Mycophenolate mofetil—psoriasis	0.000325	0.00491	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000322	0.0175	CbGpPWpGaD
Tazarotene—Skin exfoliation—Methoxsalen—psoriasis	0.000321	0.00484	CcSEcCtD
Tazarotene—Acne—Acitretin—psoriasis	0.000317	0.00478	CcSEcCtD
Tazarotene—Dry skin—Clobetasol propionate—psoriasis	0.000314	0.00474	CcSEcCtD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000309	0.0167	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000309	0.0167	CbGpPWpGaD
Tazarotene—Leukoderma—Prednisolone—psoriasis	0.000304	0.00458	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.0003	0.0163	CbGpPWpGaD
Tazarotene—Leukoderma—Hydrocortisone—psoriasis	0.000296	0.00447	CcSEcCtD
Tazarotene—Skin irritation—Hydrocortisone—psoriasis	0.000291	0.00439	CcSEcCtD
Tazarotene—Blister—Hydroxyurea—psoriasis	0.00029	0.00438	CcSEcCtD
Tazarotene—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00029	0.0157	CbGpPWpGaD
Tazarotene—Application site pain—Hydrocortisone—psoriasis	0.000287	0.00432	CcSEcCtD
Tazarotene—Dry skin—Fluocinonide—psoriasis	0.000283	0.00427	CcSEcCtD
Tazarotene—Leukoderma—Triamcinolone—psoriasis	0.000279	0.00421	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00027	0.0146	CbGpPWpGaD
Tazarotene—RARG—Nuclear Receptors—PPARG—psoriasis	0.000265	0.0144	CbGpPWpGaD
Tazarotene—Dermatitis contact—Fluocinolone Acetonide—psoriasis	0.000263	0.00396	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00026	0.0141	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000258	0.014	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000258	0.014	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Methoxsalen—psoriasis	0.000255	0.00385	CcSEcCtD
Tazarotene—Skin exfoliation—Acitretin—psoriasis	0.000254	0.00384	CcSEcCtD
Tazarotene—Leukoderma—Dexamethasone—psoriasis	0.000253	0.00382	CcSEcCtD
Tazarotene—Leukoderma—Betamethasone—psoriasis	0.000253	0.00382	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000249	0.0135	CbGpPWpGaD
Tazarotene—Hypertriglyceridaemia—Cyclosporine—psoriasis	0.000247	0.00372	CcSEcCtD
Tazarotene—RARB—Nuclear Receptors—PPARG—psoriasis	0.000238	0.0129	CbGpPWpGaD
Tazarotene—Oedema peripheral—Clobetasol propionate—psoriasis	0.000234	0.00352	CcSEcCtD
Tazarotene—Pain—Calcipotriol—psoriasis	0.00023	0.00348	CcSEcCtD
Tazarotene—RARA—Nuclear Receptors—PPARG—psoriasis	0.000228	0.0124	CbGpPWpGaD
Tazarotene—RXRB—Nuclear Receptors—PPARG—psoriasis	0.000228	0.0124	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Calcitriol—psoriasis	0.000228	0.00343	CcSEcCtD
Tazarotene—Dry skin—Methoxsalen—psoriasis	0.000224	0.00337	CcSEcCtD
Tazarotene—Leukoderma—Prednisone—psoriasis	0.000221	0.00333	CcSEcCtD
Tazarotene—Blood triglycerides increased—Cyclosporine—psoriasis	0.000216	0.00326	CcSEcCtD
Tazarotene—Eczema—Acitretin—psoriasis	0.000215	0.00325	CcSEcCtD
Tazarotene—Eczema—Fluocinolone Acetonide—psoriasis	0.000215	0.00324	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Hydrocortisone—psoriasis	0.000212	0.00319	CcSEcCtD
Tazarotene—RARG—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000209	0.0114	CbGpPWpGaD
Tazarotene—Acne—Mycophenolic acid—psoriasis	0.000208	0.00314	CcSEcCtD
Tazarotene—Erythema—Clobetasol propionate—psoriasis	0.000206	0.00311	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000204	0.0111	CbGpPWpGaD
Tazarotene—Burning sensation—Cyclosporine—psoriasis	0.000204	0.00308	CcSEcCtD
Tazarotene—Dermatitis bullous—Acitretin—psoriasis	0.000202	0.00305	CcSEcCtD
Tazarotene—Skin exfoliation—Hydroxyurea—psoriasis	0.0002	0.00301	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Triamcinolone—psoriasis	0.000199	0.00301	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000196	0.0106	CbGpPWpGaD
Tazarotene—Photosensitivity reaction—Methoxsalen—psoriasis	0.000193	0.0029	CcSEcCtD
Tazarotene—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000191	0.0103	CbGpPWpGaD
Tazarotene—Pruritus—Calcipotriol—psoriasis	0.000191	0.00288	CcSEcCtD
Tazarotene—RARB—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000188	0.0102	CbGpPWpGaD
Tazarotene—Erythema—Fluocinonide—psoriasis	0.000186	0.00281	CcSEcCtD
Tazarotene—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000186	0.0101	CbGpPWpGaD
Tazarotene—Leukoderma—Methotrexate—psoriasis	0.000184	0.00278	CcSEcCtD
Tazarotene—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000184	0.00996	CbGpPWpGaD
Tazarotene—Skin hyperpigmentation—Dexamethasone—psoriasis	0.000181	0.00273	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Betamethasone—psoriasis	0.000181	0.00273	CcSEcCtD
Tazarotene—RXRB—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00018	0.00977	CbGpPWpGaD
Tazarotene—RARA—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.00018	0.00977	CbGpPWpGaD
Tazarotene—Blister—Prednisolone—psoriasis	0.000179	0.0027	CcSEcCtD
Tazarotene—Dry skin—Acitretin—psoriasis	0.000177	0.00267	CcSEcCtD
Tazarotene—Stinging—Cyclosporine—psoriasis	0.000175	0.00264	CcSEcCtD
Tazarotene—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000171	0.00928	CbGpPWpGaD
Tazarotene—Rash—Calcipotriol—psoriasis	0.00017	0.00256	CcSEcCtD
Tazarotene—Dermatitis—Calcipotriol—psoriasis	0.00017	0.00256	CcSEcCtD
Tazarotene—Acne—Cyclosporine—psoriasis	0.000169	0.00254	CcSEcCtD
Tazarotene—Blister—Triamcinolone—psoriasis	0.000165	0.00248	CcSEcCtD
Tazarotene—Acne—Mycophenolate mofetil—psoriasis	0.000164	0.00248	CcSEcCtD
Tazarotene—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000164	0.0089	CbGpPWpGaD
Tazarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000164	0.0089	CbGpPWpGaD
Tazarotene—Hypertriglyceridaemia—Prednisone—psoriasis	0.000163	0.00246	CcSEcCtD
Tazarotene—Stinging—Prednisolone—psoriasis	0.000159	0.0024	CcSEcCtD
Tazarotene—Dermatitis bullous—Hydroxyurea—psoriasis	0.000159	0.0024	CcSEcCtD
Tazarotene—Stinging—Hydrocortisone—psoriasis	0.000156	0.00235	CcSEcCtD
Tazarotene—Acne—Prednisolone—psoriasis	0.000153	0.00231	CcSEcCtD
Tazarotene—Skin discolouration—Mycophenolate mofetil—psoriasis	0.000153	0.00231	CcSEcCtD
Tazarotene—Photosensitivity reaction—Acitretin—psoriasis	0.000153	0.0023	CcSEcCtD
Tazarotene—Haemoglobin—Calcitriol—psoriasis	0.000151	0.00228	CcSEcCtD
Tazarotene—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000151	0.00818	CbGpPWpGaD
Tazarotene—Haemorrhage—Calcitriol—psoriasis	0.00015	0.00227	CcSEcCtD
Tazarotene—Acne—Hydrocortisone—psoriasis	0.00015	0.00226	CcSEcCtD
Tazarotene—Blister—Betamethasone—psoriasis	0.000149	0.00225	CcSEcCtD
Tazarotene—Blister—Dexamethasone—psoriasis	0.000149	0.00225	CcSEcCtD
Tazarotene—Erythema—Methoxsalen—psoriasis	0.000147	0.00222	CcSEcCtD
Tazarotene—Stinging—Triamcinolone—psoriasis	0.000146	0.00221	CcSEcCtD
Tazarotene—Swelling—Mycophenolic acid—psoriasis	0.000144	0.00217	CcSEcCtD
Tazarotene—Pain—Clobetasol propionate—psoriasis	0.000144	0.00217	CcSEcCtD
Tazarotene—Blood triglycerides increased—Prednisone—psoriasis	0.000143	0.00216	CcSEcCtD
Tazarotene—Acne—Triamcinolone—psoriasis	0.000141	0.00213	CcSEcCtD
Tazarotene—Skin discolouration—Hydrocortisone—psoriasis	0.00014	0.0021	CcSEcCtD
Tazarotene—Haemoglobin—Acitretin—psoriasis	0.000135	0.00203	CcSEcCtD
Tazarotene—Haemorrhage—Acitretin—psoriasis	0.000134	0.00202	CcSEcCtD
Tazarotene—Dermatitis bullous—Mycophenolic acid—psoriasis	0.000133	0.00201	CcSEcCtD
Tazarotene—RARG—Gene Expression—TARS—psoriasis	0.000133	0.00721	CbGpPWpGaD
Tazarotene—Stinging—Betamethasone—psoriasis	0.000133	0.002	CcSEcCtD
Tazarotene—Stinging—Dexamethasone—psoriasis	0.000133	0.002	CcSEcCtD
Tazarotene—RARA—Adipogenesis—SOCS1—psoriasis	0.000133	0.00719	CbGpPWpGaD
Tazarotene—Oedema peripheral—Acitretin—psoriasis	0.000132	0.00199	CcSEcCtD
Tazarotene—Skin hyperpigmentation—Methotrexate—psoriasis	0.000132	0.00199	CcSEcCtD
Tazarotene—Pain—Beclomethasone—psoriasis	0.000131	0.00198	CcSEcCtD
Tazarotene—Erythema—Calcitriol—psoriasis	0.000131	0.00197	CcSEcCtD
Tazarotene—Pain—Fluocinonide—psoriasis	0.00013	0.00196	CcSEcCtD
Tazarotene—Inflammation—Hydrocortisone—psoriasis	0.00013	0.00196	CcSEcCtD
Tazarotene—Acne—Dexamethasone—psoriasis	0.000128	0.00193	CcSEcCtD
Tazarotene—Acne—Betamethasone—psoriasis	0.000128	0.00193	CcSEcCtD
Tazarotene—Dermatitis contact—Hydrocortisone—psoriasis	0.000125	0.00188	CcSEcCtD
Tazarotene—RXRB—Regulation of Androgen receptor activity—JUN—psoriasis	0.000124	0.00672	CbGpPWpGaD
Tazarotene—Discomfort—Methoxsalen—psoriasis	0.000124	0.00186	CcSEcCtD
Tazarotene—Skin exfoliation—Hydrocortisone—psoriasis	0.00012	0.00181	CcSEcCtD
Tazarotene—Oedema—Methoxsalen—psoriasis	0.00012	0.00181	CcSEcCtD
Tazarotene—RARB—Gene Expression—TARS—psoriasis	0.000119	0.00647	CbGpPWpGaD
Tazarotene—Pruritus—Clobetasol propionate—psoriasis	0.000119	0.0018	CcSEcCtD
Tazarotene—Dermatitis contact—Triamcinolone—psoriasis	0.000117	0.00177	CcSEcCtD
Tazarotene—Erythema—Acitretin—psoriasis	0.000117	0.00176	CcSEcCtD
Tazarotene—Erythema—Fluocinolone Acetonide—psoriasis	0.000116	0.00175	CcSEcCtD
Tazarotene—Eczema—Cyclosporine—psoriasis	0.000115	0.00173	CcSEcCtD
Tazarotene—RARA—Gene Expression—TARS—psoriasis	0.000114	0.0062	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—TARS—psoriasis	0.000114	0.0062	CbGpPWpGaD
Tazarotene—Skin exfoliation—Triamcinolone—psoriasis	0.000113	0.00171	CcSEcCtD
Tazarotene—Burning sensation—Methotrexate—psoriasis	0.000113	0.0017	CcSEcCtD
Tazarotene—Acne—Prednisone—psoriasis	0.000111	0.00168	CcSEcCtD
Tazarotene—Discomfort—Calcitriol—psoriasis	0.00011	0.00166	CcSEcCtD
Tazarotene—Dermatitis bullous—Cyclosporine—psoriasis	0.000108	0.00162	CcSEcCtD
Tazarotene—Pruritus—Fluocinonide—psoriasis	0.000108	0.00162	CcSEcCtD
Tazarotene—Dermatitis contact—Betamethasone—psoriasis	0.000106	0.0016	CcSEcCtD
Tazarotene—Dermatitis contact—Dexamethasone—psoriasis	0.000106	0.0016	CcSEcCtD
Tazarotene—Rash—Clobetasol propionate—psoriasis	0.000106	0.0016	CcSEcCtD
Tazarotene—Dermatitis—Clobetasol propionate—psoriasis	0.000106	0.0016	CcSEcCtD
Tazarotene—Haemoglobin—Hydroxyurea—psoriasis	0.000106	0.00159	CcSEcCtD
Tazarotene—Haemorrhage—Hydroxyurea—psoriasis	0.000105	0.00158	CcSEcCtD
Tazarotene—Dermatitis bullous—Mycophenolate mofetil—psoriasis	0.000105	0.00158	CcSEcCtD
Tazarotene—Skin exfoliation—Betamethasone—psoriasis	0.000103	0.00155	CcSEcCtD
Tazarotene—Skin exfoliation—Dexamethasone—psoriasis	0.000103	0.00155	CcSEcCtD
Tazarotene—Eczema—Hydrocortisone—psoriasis	0.000102	0.00153	CcSEcCtD
Tazarotene—Discomfort—Acitretin—psoriasis	9.8e-05	0.00148	CcSEcCtD
Tazarotene—Dermatitis bullous—Prednisolone—psoriasis	9.8e-05	0.00148	CcSEcCtD
Tazarotene—RARA—Adipogenesis—LEP—psoriasis	9.78e-05	0.00531	CbGpPWpGaD
Tazarotene—Rash—Beclomethasone—psoriasis	9.67e-05	0.00146	CcSEcCtD
Tazarotene—Dermatitis—Beclomethasone—psoriasis	9.66e-05	0.00146	CcSEcCtD
Tazarotene—Rash—Fluocinonide—psoriasis	9.58e-05	0.00144	CcSEcCtD
Tazarotene—Dermatitis—Fluocinonide—psoriasis	9.57e-05	0.00144	CcSEcCtD
Tazarotene—Oedema—Acitretin—psoriasis	9.51e-05	0.00143	CcSEcCtD
Tazarotene—Oedema—Fluocinolone Acetonide—psoriasis	9.48e-05	0.00143	CcSEcCtD
Tazarotene—Dry skin—Cyclosporine—psoriasis	9.43e-05	0.00142	CcSEcCtD
Tazarotene—Erythema—Hydroxyurea—psoriasis	9.15e-05	0.00138	CcSEcCtD
Tazarotene—Pain—Calcitriol—psoriasis	9.14e-05	0.00138	CcSEcCtD
Tazarotene—Dermatitis bullous—Triamcinolone—psoriasis	9.01e-05	0.00136	CcSEcCtD
Tazarotene—Skin exfoliation—Prednisone—psoriasis	8.95e-05	0.00135	CcSEcCtD
Tazarotene—Haemoglobin—Mycophenolic acid—psoriasis	8.85e-05	0.00133	CcSEcCtD
Tazarotene—Haemorrhage—Mycophenolic acid—psoriasis	8.8e-05	0.00133	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—CARM1—psoriasis	8.69e-05	0.00471	CbGpPWpGaD
Tazarotene—Skin discolouration—Methotrexate—psoriasis	8.68e-05	0.00131	CcSEcCtD
Tazarotene—Oedema peripheral—Mycophenolic acid—psoriasis	8.67e-05	0.00131	CcSEcCtD
Tazarotene—Dry skin—Prednisolone—psoriasis	8.59e-05	0.00129	CcSEcCtD
Tazarotene—RARA—Adipogenesis—PPARG—psoriasis	8.52e-05	0.00462	CbGpPWpGaD
Tazarotene—Pruritus—Methoxsalen—psoriasis	8.49e-05	0.00128	CcSEcCtD
Tazarotene—Dry skin—Hydrocortisone—psoriasis	8.38e-05	0.00126	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	8.32e-05	0.00451	CbGpPWpGaD
Tazarotene—Dermatitis bullous—Betamethasone—psoriasis	8.18e-05	0.00123	CcSEcCtD
Tazarotene—Dermatitis bullous—Dexamethasone—psoriasis	8.18e-05	0.00123	CcSEcCtD
Tazarotene—Pain—Acitretin—psoriasis	8.13e-05	0.00123	CcSEcCtD
Tazarotene—Pain—Fluocinolone Acetonide—psoriasis	8.11e-05	0.00122	CcSEcCtD
Tazarotene—Inflammation—Methotrexate—psoriasis	8.08e-05	0.00122	CcSEcCtD
Tazarotene—CYP2C8—Biological oxidations—CYP2S1—psoriasis	8.01e-05	0.00434	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7.98e-05	0.00433	CbGpPWpGaD
Tazarotene—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	7.9e-05	0.00428	CbGpPWpGaD
Tazarotene—RARB—Generic Transcription Pathway—CARM1—psoriasis	7.8e-05	0.00423	CbGpPWpGaD
Tazarotene—Discomfort—Hydroxyurea—psoriasis	7.7e-05	0.00116	CcSEcCtD
Tazarotene—Pruritus—Calcitriol—psoriasis	7.56e-05	0.00114	CcSEcCtD
Tazarotene—Rash—Methoxsalen—psoriasis	7.56e-05	0.00114	CcSEcCtD
Tazarotene—Dermatitis—Methoxsalen—psoriasis	7.56e-05	0.00114	CcSEcCtD
Tazarotene—Skin exfoliation—Methotrexate—psoriasis	7.48e-05	0.00113	CcSEcCtD
Tazarotene—RARA—Generic Transcription Pathway—CARM1—psoriasis	7.47e-05	0.00405	CbGpPWpGaD
Tazarotene—RXRB—Generic Transcription Pathway—CARM1—psoriasis	7.47e-05	0.00405	CbGpPWpGaD
Tazarotene—Oedema—Hydroxyurea—psoriasis	7.47e-05	0.00113	CcSEcCtD
Tazarotene—Dry skin—Dexamethasone—psoriasis	7.16e-05	0.00108	CcSEcCtD
Tazarotene—Dry skin—Betamethasone—psoriasis	7.16e-05	0.00108	CcSEcCtD
Tazarotene—Haemoglobin—Cyclosporine—psoriasis	7.16e-05	0.00108	CcSEcCtD
Tazarotene—Haemorrhage—Cyclosporine—psoriasis	7.12e-05	0.00107	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.99e-05	0.00379	CbGpPWpGaD
Tazarotene—Haemoglobin—Mycophenolate mofetil—psoriasis	6.98e-05	0.00105	CcSEcCtD
Tazarotene—Haemorrhage—Mycophenolate mofetil—psoriasis	6.95e-05	0.00105	CcSEcCtD
Tazarotene—Oedema peripheral—Mycophenolate mofetil—psoriasis	6.84e-05	0.00103	CcSEcCtD
Tazarotene—Rash—Calcitriol—psoriasis	6.74e-05	0.00102	CcSEcCtD
Tazarotene—Dermatitis—Calcitriol—psoriasis	6.73e-05	0.00102	CcSEcCtD
Tazarotene—Pruritus—Acitretin—psoriasis	6.73e-05	0.00101	CcSEcCtD
Tazarotene—Pruritus—Fluocinolone Acetonide—psoriasis	6.71e-05	0.00101	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.7e-05	0.00363	CbGpPWpGaD
Tazarotene—Haemoglobin—Prednisolone—psoriasis	6.51e-05	0.000982	CcSEcCtD
Tazarotene—Haemorrhage—Prednisolone—psoriasis	6.48e-05	0.000977	CcSEcCtD
Tazarotene—Discomfort—Mycophenolic acid—psoriasis	6.45e-05	0.000972	CcSEcCtD
Tazarotene—Pain—Hydroxyurea—psoriasis	6.38e-05	0.000963	CcSEcCtD
Tazarotene—Haemoglobin—Hydrocortisone—psoriasis	6.36e-05	0.000959	CcSEcCtD
Tazarotene—Haemorrhage—Hydrocortisone—psoriasis	6.33e-05	0.000954	CcSEcCtD
Tazarotene—Oedema—Mycophenolic acid—psoriasis	6.25e-05	0.000943	CcSEcCtD
Tazarotene—Dry skin—Prednisone—psoriasis	6.24e-05	0.000941	CcSEcCtD
Tazarotene—Rash—Acitretin—psoriasis	6e-05	0.000904	CcSEcCtD
Tazarotene—Dermatitis—Acitretin—psoriasis	5.99e-05	0.000903	CcSEcCtD
Tazarotene—Haemoglobin—Triamcinolone—psoriasis	5.99e-05	0.000903	CcSEcCtD
Tazarotene—Rash—Fluocinolone Acetonide—psoriasis	5.98e-05	0.000901	CcSEcCtD
Tazarotene—Dermatitis—Fluocinolone Acetonide—psoriasis	5.97e-05	0.000901	CcSEcCtD
Tazarotene—Haemorrhage—Triamcinolone—psoriasis	5.96e-05	0.000898	CcSEcCtD
Tazarotene—Erythema—Prednisolone—psoriasis	5.64e-05	0.00085	CcSEcCtD
Tazarotene—Erythema—Hydrocortisone—psoriasis	5.51e-05	0.000831	CcSEcCtD
Tazarotene—Haemoglobin—Betamethasone—psoriasis	5.43e-05	0.000819	CcSEcCtD
Tazarotene—Haemoglobin—Dexamethasone—psoriasis	5.43e-05	0.000819	CcSEcCtD
Tazarotene—Haemorrhage—Betamethasone—psoriasis	5.41e-05	0.000815	CcSEcCtD
Tazarotene—Haemorrhage—Dexamethasone—psoriasis	5.41e-05	0.000815	CcSEcCtD
Tazarotene—Pain—Mycophenolic acid—psoriasis	5.35e-05	0.000806	CcSEcCtD
Tazarotene—RARA—Adipogenesis—STAT3—psoriasis	5.23e-05	0.00284	CbGpPWpGaD
Tazarotene—Discomfort—Cyclosporine—psoriasis	5.21e-05	0.000786	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—VDR—psoriasis	5.19e-05	0.00282	CbGpPWpGaD
Tazarotene—Erythema—Triamcinolone—psoriasis	5.19e-05	0.000782	CcSEcCtD
Tazarotene—Discomfort—Mycophenolate mofetil—psoriasis	5.09e-05	0.000767	CcSEcCtD
Tazarotene—Oedema—Cyclosporine—psoriasis	5.06e-05	0.000763	CcSEcCtD
Tazarotene—Oedema—Mycophenolate mofetil—psoriasis	4.94e-05	0.000744	CcSEcCtD
Tazarotene—Discomfort—Prednisolone—psoriasis	4.74e-05	0.000715	CcSEcCtD
Tazarotene—Haemoglobin—Prednisone—psoriasis	4.73e-05	0.000713	CcSEcCtD
Tazarotene—Haemorrhage—Prednisone—psoriasis	4.71e-05	0.00071	CcSEcCtD
Tazarotene—Rash—Hydroxyurea—psoriasis	4.71e-05	0.00071	CcSEcCtD
Tazarotene—Erythema—Dexamethasone—psoriasis	4.71e-05	0.00071	CcSEcCtD
Tazarotene—Erythema—Betamethasone—psoriasis	4.71e-05	0.00071	CcSEcCtD
Tazarotene—Dermatitis—Hydroxyurea—psoriasis	4.7e-05	0.000709	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—VDR—psoriasis	4.66e-05	0.00253	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.63e-05	0.00251	CbGpPWpGaD
Tazarotene—Discomfort—Hydrocortisone—psoriasis	4.63e-05	0.000699	CcSEcCtD
Tazarotene—Oedema—Prednisolone—psoriasis	4.6e-05	0.000694	CcSEcCtD
Tazarotene—RARA—Adipogenesis—TNF—psoriasis	4.53e-05	0.00245	CbGpPWpGaD
Tazarotene—Oedema—Hydrocortisone—psoriasis	4.5e-05	0.000678	CcSEcCtD
Tazarotene—Photosensitivity reaction—Methotrexate—psoriasis	4.49e-05	0.000677	CcSEcCtD
Tazarotene—RXRB—Generic Transcription Pathway—VDR—psoriasis	4.46e-05	0.00242	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—VDR—psoriasis	4.46e-05	0.00242	CbGpPWpGaD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.46e-05	0.00242	CbGpPWpGaD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.44e-05	0.00241	CbGpPWpGaD
Tazarotene—Pruritus—Mycophenolic acid—psoriasis	4.42e-05	0.000667	CcSEcCtD
Tazarotene—Discomfort—Triamcinolone—psoriasis	4.36e-05	0.000658	CcSEcCtD
Tazarotene—Pain—Cyclosporine—psoriasis	4.33e-05	0.000652	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.28e-05	0.00232	CbGpPWpGaD
Tazarotene—Oedema—Triamcinolone—psoriasis	4.23e-05	0.000638	CcSEcCtD
Tazarotene—Pain—Mycophenolate mofetil—psoriasis	4.22e-05	0.000636	CcSEcCtD
Tazarotene—RARG—Gene Expression—CARM1—psoriasis	4.19e-05	0.00227	CbGpPWpGaD
Tazarotene—Erythema—Prednisone—psoriasis	4.1e-05	0.000618	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.05e-05	0.0022	CbGpPWpGaD
Tazarotene—Discomfort—Betamethasone—psoriasis	3.96e-05	0.000597	CcSEcCtD
Tazarotene—Discomfort—Dexamethasone—psoriasis	3.96e-05	0.000597	CcSEcCtD
Tazarotene—Haemoglobin—Methotrexate—psoriasis	3.96e-05	0.000596	CcSEcCtD
Tazarotene—Rash—Mycophenolic acid—psoriasis	3.94e-05	0.000594	CcSEcCtD
Tazarotene—Dermatitis—Mycophenolic acid—psoriasis	3.94e-05	0.000594	CcSEcCtD
Tazarotene—Pain—Prednisolone—psoriasis	3.94e-05	0.000594	CcSEcCtD
Tazarotene—Haemorrhage—Methotrexate—psoriasis	3.94e-05	0.000593	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.88e-05	0.00211	CbGpPWpGaD
Tazarotene—Pain—Hydrocortisone—psoriasis	3.84e-05	0.00058	CcSEcCtD
Tazarotene—Oedema—Dexamethasone—psoriasis	3.84e-05	0.000579	CcSEcCtD
Tazarotene—Oedema—Betamethasone—psoriasis	3.84e-05	0.000579	CcSEcCtD
Tazarotene—RARB—Gene Expression—CARM1—psoriasis	3.75e-05	0.00204	CbGpPWpGaD
Tazarotene—RARA—Adipogenesis—IL6—psoriasis	3.65e-05	0.00198	CbGpPWpGaD
Tazarotene—Pain—Triamcinolone—psoriasis	3.62e-05	0.000546	CcSEcCtD
Tazarotene—RARG—Generic Transcription Pathway—PPARG—psoriasis	3.62e-05	0.00196	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—CARM1—psoriasis	3.6e-05	0.00195	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—CARM1—psoriasis	3.6e-05	0.00195	CbGpPWpGaD
Tazarotene—Pruritus—Cyclosporine—psoriasis	3.58e-05	0.00054	CcSEcCtD
Tazarotene—Pruritus—Mycophenolate mofetil—psoriasis	3.49e-05	0.000526	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.47e-05	0.00188	CbGpPWpGaD
Tazarotene—Discomfort—Prednisone—psoriasis	3.45e-05	0.00052	CcSEcCtD
Tazarotene—Erythema—Methotrexate—psoriasis	3.43e-05	0.000516	CcSEcCtD
Tazarotene—Oedema—Prednisone—psoriasis	3.35e-05	0.000504	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.33e-05	0.0018	CbGpPWpGaD
Tazarotene—Pain—Betamethasone—psoriasis	3.28e-05	0.000495	CcSEcCtD
Tazarotene—Pain—Dexamethasone—psoriasis	3.28e-05	0.000495	CcSEcCtD
Tazarotene—RARB—Generic Transcription Pathway—PPARG—psoriasis	3.25e-05	0.00176	CbGpPWpGaD
Tazarotene—Rash—Cyclosporine—psoriasis	3.19e-05	0.000481	CcSEcCtD
Tazarotene—Dermatitis—Cyclosporine—psoriasis	3.19e-05	0.00048	CcSEcCtD
Tazarotene—Pruritus—Hydrocortisone—psoriasis	3.18e-05	0.00048	CcSEcCtD
Tazarotene—Rash—Mycophenolate mofetil—psoriasis	3.11e-05	0.000469	CcSEcCtD
Tazarotene—RXRB—Generic Transcription Pathway—PPARG—psoriasis	3.11e-05	0.00169	CbGpPWpGaD
Tazarotene—RARA—Generic Transcription Pathway—PPARG—psoriasis	3.11e-05	0.00169	CbGpPWpGaD
Tazarotene—Dermatitis—Mycophenolate mofetil—psoriasis	3.11e-05	0.000469	CcSEcCtD
Tazarotene—RARB—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.06e-05	0.00166	CbGpPWpGaD
Tazarotene—Pruritus—Triamcinolone—psoriasis	3e-05	0.000452	CcSEcCtD
Tazarotene—RARA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.93e-05	0.00159	CbGpPWpGaD
Tazarotene—Rash—Prednisolone—psoriasis	2.9e-05	0.000438	CcSEcCtD
Tazarotene—Dermatitis—Prednisolone—psoriasis	2.9e-05	0.000437	CcSEcCtD
Tazarotene—Discomfort—Methotrexate—psoriasis	2.88e-05	0.000434	CcSEcCtD
Tazarotene—Rash—Hydrocortisone—psoriasis	2.83e-05	0.000427	CcSEcCtD
Tazarotene—Dermatitis—Hydrocortisone—psoriasis	2.83e-05	0.000427	CcSEcCtD
Tazarotene—Pruritus—Dexamethasone—psoriasis	2.72e-05	0.00041	CcSEcCtD
Tazarotene—Pruritus—Betamethasone—psoriasis	2.72e-05	0.00041	CcSEcCtD
Tazarotene—Rash—Triamcinolone—psoriasis	2.67e-05	0.000402	CcSEcCtD
Tazarotene—Dermatitis—Triamcinolone—psoriasis	2.67e-05	0.000402	CcSEcCtD
Tazarotene—RARG—Gene Expression—VDR—psoriasis	2.5e-05	0.00136	CbGpPWpGaD
Tazarotene—Rash—Betamethasone—psoriasis	2.42e-05	0.000365	CcSEcCtD
Tazarotene—Rash—Dexamethasone—psoriasis	2.42e-05	0.000365	CcSEcCtD
Tazarotene—Dermatitis—Dexamethasone—psoriasis	2.42e-05	0.000365	CcSEcCtD
Tazarotene—Dermatitis—Betamethasone—psoriasis	2.42e-05	0.000365	CcSEcCtD
Tazarotene—Pain—Methotrexate—psoriasis	2.39e-05	0.00036	CcSEcCtD
Tazarotene—Pruritus—Prednisone—psoriasis	2.37e-05	0.000357	CcSEcCtD
Tazarotene—RARB—Gene Expression—VDR—psoriasis	2.24e-05	0.00122	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—VDR—psoriasis	2.15e-05	0.00117	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—VDR—psoriasis	2.15e-05	0.00117	CbGpPWpGaD
Tazarotene—Rash—Prednisone—psoriasis	2.11e-05	0.000318	CcSEcCtD
Tazarotene—Dermatitis—Prednisone—psoriasis	2.11e-05	0.000318	CcSEcCtD
Tazarotene—Pruritus—Methotrexate—psoriasis	1.98e-05	0.000298	CcSEcCtD
Tazarotene—Rash—Methotrexate—psoriasis	1.76e-05	0.000266	CcSEcCtD
Tazarotene—Dermatitis—Methotrexate—psoriasis	1.76e-05	0.000266	CcSEcCtD
Tazarotene—RARG—Gene Expression—PPARG—psoriasis	1.74e-05	0.000945	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—NDUFA5—psoriasis	1.61e-05	0.000874	CbGpPWpGaD
Tazarotene—RARB—Gene Expression—PPARG—psoriasis	1.56e-05	0.000848	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.5e-05	0.000815	CbGpPWpGaD
Tazarotene—RXRB—Gene Expression—PPARG—psoriasis	1.5e-05	0.000813	CbGpPWpGaD
Tazarotene—RARA—Gene Expression—PPARG—psoriasis	1.5e-05	0.000813	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CYP2S1—psoriasis	1.37e-05	0.000743	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.18e-06	0.000389	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CARM1—psoriasis	6.69e-06	0.000363	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.25e-06	0.000339	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—CAT—psoriasis	4.11e-06	0.000223	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—APOE—psoriasis	3.2e-06	0.000173	CbGpPWpGaD
Tazarotene—CYP2C8—Metabolism—PPARG—psoriasis	2.78e-06	0.000151	CbGpPWpGaD
